Ad is loading...
FSMAX
Price
$92.50
Change
-$1.21 (-1.29%)
Updated
Nov 15 closing price
TRMNX
Price
$21.35
Change
-$0.29 (-1.34%)
Updated
Nov 15 closing price
Ad is loading...

FSMAX vs TRMNX

Header iconFSMAX vs TRMNX Comparison
Open Charts FSMAX vs TRMNXBanner chart's image
Fidelity Extended Market Index
Price$92.50
Change-$1.21 (-1.29%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Index
Price$21.35
Change-$0.29 (-1.34%)
VolumeN/A
CapitalizationN/A
FSMAX vs TRMNX Comparison Chart
Loading...
View a ticker or compare two or three
VS
FSMAX vs. TRMNX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FSMAX is a StrongSell and TRMNX is a Buy.

FUNDAMENTALS
Fundamentals
FSMAX has more cash in the bank: 40B vs. TRMNX (231M). FSMAX pays higher dividends than TRMNX: FSMAX (1.10) vs TRMNX (0.70). FSMAX was incepted earlier than TRMNX: FSMAX (13 years) vs TRMNX (9 years). TRMNX is a more actively managed with annual turnover of: 29.50 vs. FSMAX (18.00). FSMAX has a lower initial minimum investment than TRMNX: FSMAX (0) vs TRMNX (2500). TRMNX (36.90) and FSMAX (35.21) have marching annual gain over last year. TRMNX return over 5 years is better than : 60.54 vs. FSMAX (51.19).
FSMAXTRMNXFSMAX / TRMNX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence13 years9 years-
Gain YTD18.49920.96388%
Front LoadN/AN/A-
Min. Initial Investment02500-
Min. Initial Investment IRAN/AN/A-
Net Assets40B231M17,316%
Annual Yield % from dividends1.100.70157%
Returns for 1 year35.2136.9095%
Returns for 3 years-0.08-0.6613%
Returns for 5 years51.1960.5485%
Returns for 10 years81.58N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HRB60.080.94
+1.59%
H&R Block
DE398.954.31
+1.09%
Deere & Company
GNE15.790.02
+0.13%
GENIE ENERGY Ltd
CMRE14.39-0.16
-1.10%
Costamare
SPRO1.18-0.07
-5.60%
Spero Therapeutics